DP
XERS icon

Diadema Partners’s Xeris Biopharma Holdings XERS Stock Holding History

Diadema Partners’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.05M Hold
132,746
– – 0.13% 103
2026
Q1 		$770K Sell
132,746
-37,822
-22% -$251K 0.13% 94
2025
Q4 		$1.34M Buy
170,568
+95,815
+128% +$754K 0.23% 83
2025
Q3 		$608K Buy
+74,753
New +$497K 0.16% 95

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Diadema Partners's XERS Position: Q2 2026 in Review

Diadema Partners held its Xeris Biopharma Holdings (XERS) position steady in Q2 2026 at 132,746 shares worth $1.05M. The position accounts for 0.13% of the portfolio, ranked #103.

Diadema Partners first reported a position in XERS in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.34M in Q4 2025. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Diadema Partners held 132,746 shares of Xeris Biopharma Holdings worth $1.05M as of Q2 2026.
  • Diadema Partners left its Xeris Biopharma Holdings share count unchanged in Q2 2026.
  • Xeris Biopharma Holdings made up 0.13% of Diadema Partners's portfolio in Q2 2026, its #103 holding.
  • Diadema Partners first reported a position in Xeris Biopharma Holdings in Q3 2025 and has held it in 4 quarters since.
  • Diadema Partners's Xeris Biopharma Holdings position peaked at $1.34M in Q4 2025.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.